The pharmacoeconomics of acne treatment: Where are we heading?

References

• Bergfield W. F. The evaluation and management of acne: Economic considerations. J Am Acad Dermatol 1995; 32: S52–6
   Google Scholar
• Stern R. S. Acne therapy: Medication use and sources of care in office‐based practice. Arch Dermatol 1996; 132: 776–80
   PubMed Web of Science ®Google Scholar
• Maddin W. S., Landells I. D. M. Treatment of acne vulgaris and prevention of acne scarring: Canadian Consensus Guidelines. J Cutan Med Surg 2000; 4(suppl 4)2–13
   PubMedGoogle Scholar
• Krowchuk D. P. Managing acne in adolescents. Pediatr Clin North Am 2000; 47: 841–57
   PubMedGoogle Scholar
• Robertson J., Lang D., Hill S. Use of pharmacoeconomics in prescribing research. Part 1: Costs – moving beyond the acquisition price for drugs. J Clin Pharm Ther 2003; 28: 73–9
   PubMedGoogle Scholar
• Hay J. Pharmacoeconomic guidelines: Where do we go from here?. Value Health 2001; 4: 211
   PubMedGoogle Scholar
• Meltzer M. I. Introduction to health economics for physicians. Lancet 2001; 358: 993–8
   PubMed Web of Science ®Google Scholar
• Berger M. Pharmacoeconomic guidelines: Where do we go from here?. Value Health 2001; 4: 278, (letter)
   PubMedGoogle Scholar
• Rodriguez‐Monguio R., Otero M., Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003; 21: 623–50
   PubMed Web of Science ®Google Scholar
• Briggs A. Handling uncertainty in economic evaluation. BMJ 1999; 319: 120
   PubMedGoogle Scholar
• Hill S. R., Mitchell A. S., Henry D. A. Problems with the interpretation of pharmacoeconomic analyses. A review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283: 2116–21
   PubMed Web of Science ®Google Scholar
• Newby D., Hill S. Use of pharmacoeconomics in prescribing research. Part 2: Cost‐minimization analysis – when are two therapies equal?. J Clin Pharm Ther 2003; 28: 145–50
   PubMedGoogle Scholar
• Lopert R., Lang D. L., Hill S. R. Use of pharmacoeconomics in prescribing research. Part 3: Cost‐effectiveness analysis – a technique for decision‐making at the margin. J Clin Pharm Ther 2003; 28: 243–9
   PubMedGoogle Scholar
• Brinsmead R., Hill S. Use of pharmacoeconomics in prescribing research. Part 4: Is cost‐utility analysis a useful tool?. J Clin Pharm Ther 2003; 28: 339–46
   PubMedGoogle Scholar
• Dolan P., Gudex C., Kind P., Williams A. Valuing health states: A comparison of methods. J Health Econ 1996; 15: 209–31
   PubMed Web of Science ®Google Scholar
• Chiou C. F., Hay J. W., Wallace J. F., Bloom B. S., et al. Development and validation of a grading system for the quality of cost‐effectiveness studies. Med Care 2003; 41: 32–44
   PubMed Web of Science ®Google Scholar
• Stern R. S., Pass T. M., Komaroff A. L. Topical versus systemic agent treatment for papulopustular acne: A cost‐effective analysis. Arch Dermatol 1984; 120: 1571–8
   PubMedGoogle Scholar
• Cunliffe W. J., Gray J. A., Macdonald‐Hull S., Hughes B. R., et al. Cost effectiveness of isotretinoin. J Dermatolog Treat 1991; 1: 285–8
   Google Scholar
• Simpson N. B. Social and economic aspects of acne and the cost‐effectiveness of isotretinoin. J Dermatolog Treat 1993; 4(suppl 2)S6–S9
   Google Scholar
• Warren K. J., Cruz P. D., Jr. Clinical outcome and cost analysis of isotretinoin versus conventional regimens in the treatment of moderate acne vulgaris in male patients. Pediatr Dermatol 1998; 15: 329–31
   PubMedGoogle Scholar
• Wessels F., Anderson A. N., Kropman K. The cost‐effectiveness of isotretinoin in the treatment of acne. Part 3. A cost‐minimization pharmaco‐economic model. S Afr Med J 1999; 89: 791–4
   PubMedGoogle Scholar
• Bossuyt L., Bosschaert J., Richert B., Cromphaut P., et al. Lymecycline in the treatment of acne: An efficacious, safe and cost‐effective alternative to minocycline. Eur J Dermatol 2003; 13: 130–5
   PubMed Web of Science ®Google Scholar
• Lee M. L., Cooper A. Isotretinoin: Cost‐benefit study. Australas J Dermatol 1991; 32: 17–20
   PubMedGoogle Scholar
• Newton J. N. How cost‐effective is oral isotretinoin?. Dermatology 1997; 195(suppl 1)10–14, discussion 38–40
   PubMedGoogle Scholar
• Wishart J., Villiger J. Cost‐benefit of isotretinoin (Roaccutane). N Z Med J 1991; 104: 291–9
   PubMedGoogle Scholar
• Fleischer A. B. Original unpublished work: data analysis of U.S. National Ambulatory Medical Care Survey. 2003
   Google Scholar
• Wert S. Identification and management of oral isotretinoin use inconsistent with product labeling. Manag Care Interface 2003; 16: 41–43; 55
   PubMedGoogle Scholar
• Berwick D. M. Cost‐effectiveness analysis in clinical practice. Is a truce possible?. Arch Dermatol 1984; 120: 1569–70
   PubMedGoogle Scholar
• Tan J. K. Perspectives on isotretinoin and the Canadian Consensus Guidelines on treatment of acne. Skin Therapy Lett 2000; 6: 1–4
   PubMedGoogle Scholar
• Ortonne J. P. Oral isotretinoin treatment policy. Do we all agree?. Dermatology 1997; 195(suppl 1)34–7, discussion 38–40
   PubMedGoogle Scholar
• Wysowski D. K., Swann J., Vega A. Use of isotretinoin (Accutane) in the United States: Rapid increase from 1992 through 2000. J Am Acad Dermatol 2002; 46: 505–9
   PubMedGoogle Scholar
• Stern R. S. Medication and medical service utilization for acne 1995–1998. J Am Acad Dermatol 2000; 43: 1042–8
   PubMedGoogle Scholar
• Jick S. S., Kremers H. M., Vasilakis‐Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136: 1231–6
   PubMedGoogle Scholar
• Koo J. The psychosocial impact of acne: Patients' perceptions. J Am Acad Dermatol 1995; 32: S26–30
   PubMed Web of Science ®Google Scholar
• Simpson N. Effect of isotretinoin on the quality of life of patients with acne. Pharmacoeconomics 1994; 6: 108–13
   PubMed Web of Science ®Google Scholar
• Galvin S. A., Gilbert R., Baker M., et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998; 139(suppl 52)34–40
   PubMedGoogle Scholar
• Shalita A., Weiss J. S., Chalker D. K., et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: A multicenter trial. J Am Acad Dermatol 1996; 34: 482–5
   PubMed Web of Science ®Google Scholar
• Brand B., Gilbert R., Baker M. D., et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003; 49(suppl 3)S227–32
   Google Scholar
• Greenspan A. H., Gilbert R., Baker M. D. Cumulative irritancy potential of adapalene cream 0.1% compared to adapalene gel 0.1% and several tretinoin formulas. Poster presentation at Academy 2001, The American Academy of Dermatology, Anaheim, CA, July 28 to August 1, 2001
   Google Scholar
• Balkrishnan R., Fleischer A. B., Jr., Paruthi S., Feldman S. R. Physicians underutilize topical retinoids in the management of acne vulgaris: Analysis of US National Practice Data. J Dermatolog Treat 2003; 14: 172–6
   PubMedGoogle Scholar
• Gollnick H., Cunliffe W., Berson D., et al. Management of acne: A report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49: S1–37
   PubMed Web of Science ®Google Scholar
• Motley R. J., Finlay A. Y. How much disability is caused by acne?. Clin Exp Dermatol 1989; 14: 194–8
   PubMed Web of Science ®Google Scholar
• Newton J. N., Mallon E., Klassen A., Ryan T. J., Finlay A. Y. The effectiveness of acne treatment: An assessment by patients of the outcome of therapy. Br J Dermatol 1997; 137: 563–7
   PubMed Web of Science ®Google Scholar
• Brown G. C., Sharma S., Brown M. M., Garrett S. Evidence‐based medicine and cost‐effectiveness. J Health Care Finance 1999; 26: 14–23
   PubMedGoogle Scholar
• Anell A., Norinder A. Health outcome measures used in cost‐effectiveness studies: A review of original articles published between 1986 and 1996. Health Policy 2000; 51: 87–99
   PubMedGoogle Scholar
• Raisch D. W. Understanding quality‐adjusted life years and their application to pharmacoeconomic research. Ann Pharmacother 2000; 34: 906–14
   PubMed Web of Science ®Google Scholar
• Girman C. J., Hartmaier S., Thiboutot D., et al. Evaluating health‐related quality of life in patients with facial acne: Development of a self‐administered questionnaire for clinical trials. Qual Life Res 1996; 5: 481–90
   PubMed Web of Science ®Google Scholar
• Anderson R., Rajagopalan R. Responsiveness of the Dermatology‐specific Quality of Life (DSQL) instrument to treatment for acne vulgaris in a placebo‐controlled clinical trial. Qual Life Res 1998; 7: 723–34
   PubMed Web of Science ®Google Scholar
• Finlay A. Y., Khan., G. K. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–16
   PubMed Web of Science ®Google Scholar
• Chren M. M., Lasek R. J., Quinn L. M., et al. Skindex, a quality‐of‐life measure for patients with skin disease: Reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707–13
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality, Management of acne. Summary – Evidence Report/Technology Assessment: Number 17. AHRQ Publication No. 01‐E018. Agency for Healthcare Research and Quality, Rockville, MD March 2001
   Google Scholar
• Cunliffe W. J. Acne and unemployment. Br J Dermatol 1986; 115: 386
   PubMed Web of Science ®Google Scholar
• Eady E. A. Bacterial resistance in acne. Dermatology 1998; 196: 59–66
   PubMed Web of Science ®Google Scholar
• Ross J. L., Snelling A. M., Carnegie E., et al. Antibiotic‐resistant acne: Lessons from Europe. Br J Dermatol 2003; 148: 467–78
   PubMed Web of Science ®Google Scholar
• Coates P., Adams C. A., Cunliffe W. J., McGinley K. T., et al. Does oral isotretinoin prevent Propionibacterium acnes resistance?. Dermatology 1997; 195(suppl 1)S4–9
   PubMedGoogle Scholar
• Gollnick H. P., Krautheim A. Topical treatment in acne: Current status and future aspects. Dermatology 2003; 206: 29–36
   PubMed Web of Science ®Google Scholar
• Siegel J. E., Torrance G. W., Russell L. B., Luce B. R., et al. Guidelines for pharmacoeconomic studies: Recommendations from the panel on cost effectiveness in health and medicine. Pharmacoeconomics 1997; 11: 150–68
   Google Scholar
• Wirtzer A. S. Treatment of acne in the fee‐for‐service and managed care settings. J Am Acad Dermatol 1995; 32: S49–51
   Google Scholar
• McConnell R. C., Fleischer A. B., Jr., Williford P. M., Feldman S. R. Most topical tretinoin treatment is for acne vulgaris through the age of 44 years: An analysis of the National Ambulatory Medical Care Survey, 1990–1994. J Am Acad Dermatol 1998; 38: 221–6
   PubMedGoogle Scholar
• Yonkosky D. M., Pochi P. E. Acne vulgaris in childhood. Pathogenesis and management. Dermatol Clin 1986; 4: 127–36
   PubMed Web of Science ®Google Scholar
• Feldman S. R., Fleischer A. B., Jr., Chen G. J. Is prior authorization of topical tretinoin for acne cost effective?. Am J Manag Care 1999; 5: 457–63
   PubMedGoogle Scholar
• Avorn J. Balancing the cost and value of medications: The dilemma facing clinicians. Pharmacoeconomics 2002; 20(suppl 3)S67–72
   PubMedGoogle Scholar